CNAT Research and Charts

CNAT - Conatus Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2020-07-31 (Delayed quote data 2025-06-26)

Last 0.02	Change ⇓ 0.00 (0.00%)	Volume 95
	Open 0.02	High 0.02	Low 0.02

8EMA (Daily) 0.01	40EMA (Daily) 0.02	50EMA (Daily) 0.02	STO (Daily) 33.333	MACD Hist (Daily) 0.003
8EMA (Weekly) 0.018	40EMA (Weekly) 0.08	50EMA (Weekly) 0.11	STO (Weekly) 12.105	MACD Hist (Weekly) 0.008


Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. It focuses on the development and commercialization of novel medicines to treat liver disease. The company is developing emricasan, an orally active pan-caspase protease inhibitor, for the treatment of patients with the chronic liver disease.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.